Elsaman A M, Hamed A, Radwan A R
Department of Rheumatology and Rehabilitation, Sohag University Hospital, Sohag, Egypt.
Department of Rheumatology and Rehabilitation, Minia University Hospital, Elminia, Egypt.
Korean J Pain. 2021 Jan 1;34(1):114-123. doi: 10.3344/kjp.2021.34.1.114.
Evaluation of the effectiveness of caudal epidural injection on pain, spine mobility, disease activity, and activity of daily living in axial spondyloarthritis (SpA) patients.
A total sample of 47 patients were registered in this study. They were randomly assigned into 2 groups; Group I received caudal epidural injections, ultrasound-guided, with 1% lidocaine hydrochloride mixed with triamcinolone, whereas Group II did not receive any injections. All participants fulfilled the ASAS criteria for axial SpA. Outcome measures were as follows: visual analogue scale, Oswestry disability index (ODI), modified Schober test, lateral lumbar flexion, and Ankylosing Spondylitis Disease Activity Score (ASDAS) with assessment at baseline, 2 weeks, and 8 weeks post-treatment. This clinical trial was registered on clinicaltrials.gov under the number NCT04143165.
There was a significant difference between both groups regarding pain, ODI, spine mobility and ASDAS scores in favor of group I. This effect was at its maximum after 2 weeks. Despite the decline of this effect after 2 months, the difference between the groups remained significant. Higher disease activity, younger age, and shorter disease duration were associated with better outcomes.
Epidural injection of lidocaine and triamcinolone is a cost effective and a practical technique for controlling pain, as well as improving the function of the spine and disease activity scores in axial SpA patients with acceptable complications and relatively sustained effect.
评估骶管硬膜外注射对轴性脊柱关节炎(SpA)患者疼痛、脊柱活动度、疾病活动度及日常生活活动能力的有效性。
本研究共纳入47例患者。他们被随机分为2组;第一组接受超声引导下的骶管硬膜外注射,注射药物为1%盐酸利多卡因与曲安奈德混合液,而第二组未接受任何注射。所有参与者均符合轴性SpA的ASAS标准。观察指标如下:视觉模拟评分、Oswestry功能障碍指数(ODI)、改良Schober试验、腰椎侧屈度以及强直性脊柱炎疾病活动度评分(ASDAS),在治疗前、治疗后2周和8周进行评估。该临床试验已在clinicaltrials.gov上注册,注册号为NCT04143165。
两组在疼痛、ODI、脊柱活动度和ASDAS评分方面存在显著差异,第一组更具优势。这种效果在2周后达到最大。尽管2个月后这种效果有所下降,但两组之间的差异仍然显著。疾病活动度较高、年龄较轻和病程较短与更好的结果相关。
利多卡因和曲安奈德硬膜外注射是一种经济有效的实用技术,可控制轴性SpA患者的疼痛,改善脊柱功能和疾病活动度评分,并发症可接受且效果相对持久。